Weight-loss medicines have transformed the treatment of obesity and type 2 diabetes. Among these medications, semaglutide has attracted enormous attention because it helps many people lose more weight than older treatments.
Yet as the popularity of these drugs has grown, scientists have continued to investigate whether dramatic weight loss could have unintended effects on bone health. A new study suggests that semaglutide may actually be linked to fewer bone fractures, offering reassuring news for patients and doctors alike.
The research was presented at ENDO 2026, the annual meeting of the Endocrine Society in Chicago. Researchers from Stanford University reported that people with type 2 diabetes taking semaglutide had a lower risk of fractures and greater weight loss than patients using several alternative weight-loss medications.
Bones are living tissues that constantly rebuild themselves. As people age, bone loss often occurs faster than new bone formation. This process can increase the risk of osteoporosis and fractures.
Doctors have long known that fractures can have serious consequences, especially in older adults. A broken hip, for example, may lead to lengthy hospital stays, rehabilitation, and reduced independence.
Scientists have also observed that rapid weight loss may sometimes contribute to bone thinning. Because semaglutide can produce substantial weight reduction, researchers wanted to determine whether patients taking the medication faced higher or lower fracture risks than patients taking other treatments.
To investigate, the Stanford team analyzed electronic health records from the Atropos Health Eos database. The database contains information from approximately 161 million patients treated throughout the United States. The researchers reviewed records from adults diagnosed with type 2 diabetes between 2016 and 2023.
The study excluded people who had already experienced fractures or were taking osteoporosis medications. This allowed the investigators to focus on new fractures occurring after treatment began.
More than 26,000 participants received semaglutide. The comparison group included more than 33,000 patients taking dulaglutide, phentermine/topiramate, or bupropion/naltrexone. These medications are also commonly used to manage weight or diabetes.
Researchers tracked changes in body mass index and recorded fracture events. As expected, semaglutide users lost more weight than people in the comparison group. The greater weight reduction confirmed findings from earlier studies showing semaglutide’s effectiveness for weight management.
What surprised the researchers was the difference in fracture rates. Among semaglutide users, 794 fractures occurred. In the comparison group, 1,045 fractures were recorded. After statistical analysis, semaglutide was associated with a 15 percent lower risk of fractures.
The findings suggest that semaglutide-induced weight loss may not negatively affect bone health in the way some experts had feared. In fact, the medication may be associated with better bone outcomes than several alternative therapies.
However, it is important to understand the limitations of the study. Because researchers examined existing medical records, they could identify associations but could not prove cause and effect. Other factors that were not fully measured may have influenced fracture risk.
The investigators therefore recommend future prospective studies. In these studies, patients would be followed forward in time under controlled conditions, providing stronger evidence about whether semaglutide directly protects bones.
The study highlights an important issue that often receives less attention than weight loss itself. Successful obesity treatment should not only reduce body weight but also preserve overall health, including muscle strength and bone quality. Monitoring bone health may become an increasingly important part of comprehensive weight-management programs.
Overall, this research represents an important early step in understanding how modern GLP-1 medications affect the skeleton. The large number of participants strengthens confidence in the findings, but additional research is still needed.
If future studies confirm the results, semaglutide could offer a valuable combination of benefits, helping people with type 2 diabetes lose weight while potentially lowering their risk of painful and costly bone fractures.
If you care about weight loss, please read studies that hop extract could reduce belly fat in overweight people, and early time-restricted eating could help lose weight .
For more health information, please see recent studies about a simple path to weight loss, and results showing a non-invasive treatment for obesity and diabetes.
Source: Stanford University.
